Mylan is turning to other opportunities for growth in the rapidly consolidating pharmaceutical industry after failing to acquire Irish over-the-counter drug maker Perrigo Co. plc in a bitter months-long struggle.

Perrigo shareholders spurned Mylan’s $26 billion hostile takeover bid Friday, with the generic drug giant picking up only 40 percent of Perrigo’s shares when Mylan’s offer expired Friday morning. Mylan had said it needed 50 percent of Perrigo’s shares to consummate the deal.

Mylan Chairman Robert Coury said Friday the company was already moving on. In a prepared statement, Mr. Coury said Mylan was “well positioned to quickly execute on the next strategic, value-enhancing opportunities for our business, some of which we have already identified.”

The company did not elaborate on those opportunities, but Sanford C. Bernstein & Co. senior analyst Ronny Gal identified two potential targets: Sanofi SA’s generic drug business and Pfizer’s generic drug division, if it becomes available.

Advertise with us

“They can also license additional drugs,” Mr. Gal said. “My view is that there is no shortage of opportunities for them.”

Barclays analysts Douglas Tsao and Morgan Williams were also upbeat about Mylan’s future. “With the consolidation in the generics industry, we believe Mylan has no shortage of interesting opportunities,” they wrote after the Mylan-Perrigo deal collapsed. “We think there is a lot to like in the Mylan story, perhaps even more so without Perrigo.”

Read More

Still, the end of the Perrigo deal was a setback for the 54-year-old Mr. Coury. Even though Mylan would’ve had to overcome integration challenges in melding the two companies, acquiring Perrigo would’ve given Mylan a new pipeline into the international over-the-counter consumer drug market.

And Mr. Coury had been nothing if not confident the Perrigo deal would come together.

“You and your board are unable to stop the combination,” Mr. Coury told Perrigo Chairman and CEO Joseph Papa in a letter after launching the takeover bid in September.

Advertise with us

Mylan offered $26 billion for Perrigo, translating into a modest 11.4 percent premium over Perrigo’s closing price of $156.55 on Thursday. Perrigo’s shareholders would have received $75 in cash and 2.3 Mylan shares for each Perrigo share.

Perrigo Chairman and CEO Joseph Papa Friday morning repeated his criticism of the Mylan offer, saying it “significantly undervalued” the company.

“Now that the Mylan tender offer is behind us, we look forward to continuing to create significant value for our shareholders,” he said in a prepared statement. “Our confidence in Perrigo’s compelling near- and long-term growth prospects, and our steadfast commitment to delivering returns to shareholders remain unchanged.”

Mylan finished the day up $5.58, or 13 percent, to $48.78. Perrigo closed off $9.65, or 6.1 percent, at $146.90 a share Friday.

Mylan reincorporated in the Netherlands but maintains its operational headquarters in Cecil.

Kris B. Mamula: kmamula@post-gazette.com, 412-263-1699.